Evidence map›Paper›PMID 36644819›Full record

ArticleCancer science2023

CircLASP1 silence strengthens the therapeutic effects of MK-2206 on nasopharyngeal cancer through upregulating miR-625.

Li-Na Xu, Si-Le Liu, Yang Yang, Lu Shu, Yi Sun

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Li-Na XuDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Si-Le LiuDepartment of Laboratory, Hunan Provincial People's Hospital, Changsha, Hunan Province, China.
Yang YangDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Lu ShuDepartment of Breast Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Yi SunDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China.ORCID https://orcid.org/0000-0002-5747-1351
Central South University · CNHunan Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic effects of MK-2206 are largely limited due to the complexity of the pathogenesis of nasopharyngeal cancer (NPC). Here, we aimed to investigate whether and how circLASP1 is involved in the therapeutic effects of MK-2206 on NPC. We showed circLASP1 was increased while miR-625 was decreased in NPC tissues and cell lines. CircLASP1 silence strengthened the therapeutic effects of MK-2206 via suppressing NPC cell proliferation and inducing autophagy and apoptosis in vitro. In mechanism analyses, we found that circLASP1 indirectly released AKT by directly binding to miR-625 in NPC cells, and miR-625 acted as a tumor suppressor in NPC and activated cell autophagy through inhibiting the AKT/mTOR pathway. Most importantly, knockdown of circLASP1 was revealed to enhance the therapeutic effects of MK-2206 on NPC in vivo. Our results suggest that the circLASP1/miR-625 axis is involved the therapeutic effects of MK-2206 on NPC by regulating autophagy, proliferation, and apoptosis through the AKT/mTOR pathway. miR-625 is involved in NPC tumorigenesis.

Indexed as

MicroRNAsNasopharyngeal NeoplasmsApoptosisCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHeterocyclic Compounds, 3-RingHumansNasopharyngeal CarcinomaProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesHeterocyclic Compounds, 3-RingMicroRNAsMIRN625 microRNA, humanMK 2206Proto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesautophagyCircLASP1miR-625MK-2206nasopharyngeal cancer

Identifiers

PMID36644819
PMCPMC10154807
OpenAlexW4316464517

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.